Date: 2014-09-15
Type of information: Initiation of patient enrollment
phase:
Announcement: initiation of patient enrollment
Company: Covidien (Ireland)
Product: endovascular stroke devices
Action mechanism:
Disease: acute ischemic stroke
Therapeutic area: Cardiovascular diseases - Cerebrovascular diseases
Country: USA
Trial details:
Latest
news: * On September 15, 2014, Covidien announced the start of enrollment in two clinical trials designed to further underscore the safety and effectiveness of the company’s advanced neurovascular solutions. Baptist Health Lexington in Kentucky, enrolled the first patient in the STRATIS Registry for Endovascular Stroke Devices, which will evaluate the use of all Covidien market-released stroke devices. The STRATIS Registry is a prospective, multi-center, non-randomized, observational registry designed to evaluate the use of Covidien endovascular stroke devices in patients diagnosed with an acute ischemic stroke. Covidien’s current endovascular stroke device in the U.S. is the Solitaire™ 2 revascularization device.
The STRATIS Registry will assess mechanical thrombectomy (MT) as a treatment option in patients who can’t get access to or are not eligible for IV-tPA - a medication that dissolves blood clots.
